View Future GrowthDhansa Labs 과거 순이익 실적과거 기준 점검 3/6Dhansa Labs의 수입은 연평균 -10.8%의 비율로 감소해 온 반면, Chemicals 산업은 수입이 연평균 5.8% 증가했습니다. 매출은 연평균 10.4%의 비율로 증가해 왔습니다. Dhansa Labs의 자기자본이익률은 5.6%이고 순이익률은 3.9%입니다.핵심 정보-10.82%순이익 성장률-61.05%주당순이익(EPS) 성장률Chemicals 산업 성장률17.68%매출 성장률10.43%자기자본이익률5.59%순이익률3.87%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.21 (vs ₹2.06 in FY 2025)Full year 2026 results: EPS: ₹2.21 (up from ₹2.06 in FY 2025). Revenue: ₹1.43b (up 7.5% from FY 2025). Net income: ₹55.2m (up 16% from FY 2025). Profit margin: 3.9% (up from 3.6% in FY 2025). The increase in margin was driven by higher revenue.공시 • May 23Ambey Laboratories Limited to Report Second Half, 2026 Results on May 29, 2026Ambey Laboratories Limited announced that they will report second half, 2026 results on May 29, 2026공시 • Nov 14Ambey Laboratories Limited to Report First Half, 2026 Results on Nov 14, 2025Ambey Laboratories Limited announced that they will report first half, 2026 results on Nov 14, 2025Reported Earnings • Sep 08Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.0% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.Reported Earnings • Jun 05Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.2% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.Reported Earnings • Nov 18First half 2025 earnings releasedFirst half 2025 results: EPS: ₹0.16. Net income: ₹29.7m (up ₹29.7m from 1H 2024).모든 업데이트 보기Recent updatesReported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.21 (vs ₹2.06 in FY 2025)Full year 2026 results: EPS: ₹2.21 (up from ₹2.06 in FY 2025). Revenue: ₹1.43b (up 7.5% from FY 2025). Net income: ₹55.2m (up 16% from FY 2025). Profit margin: 3.9% (up from 3.6% in FY 2025). The increase in margin was driven by higher revenue.공시 • May 23Ambey Laboratories Limited to Report Second Half, 2026 Results on May 29, 2026Ambey Laboratories Limited announced that they will report second half, 2026 results on May 29, 2026Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 37%After last week's 37% share price gain to ₹37.05, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 2.2% over the past year.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹21.90, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 49% over the past year.Valuation Update With 7 Day Price Move • Feb 26Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹23.00, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 55% over the past year.New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹899.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Market cap is less than US$10m (₹899.3m market cap, or US$9.97m).분석 기사 • Jan 08Ambey Laboratories (NSE:AMBEY) Could Be Struggling To Allocate CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹44.35, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 30% over the past year.New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹1.08b market cap, or US$12.1m).New Risk • Nov 24New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.05b market cap, or US$11.7m).분석 기사 • Nov 15There Is A Reason Ambey Laboratories Limited's (NSE:AMBEY) Price Is UndemandingWith a price-to-earnings (or "P/E") ratio of 22.6x Ambey Laboratories Limited ( NSE:AMBEY ) may be sending bullish...공시 • Nov 14Ambey Laboratories Limited to Report First Half, 2026 Results on Nov 14, 2025Ambey Laboratories Limited announced that they will report first half, 2026 results on Nov 14, 2025Board Change • Oct 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Sep 08Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.0% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.공시 • Sep 04Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025, at 15:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹44.75, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 30x in the Chemicals industry in India. Total loss to shareholders of 45% over the past year.분석 기사 • Jul 19Ambey Laboratories Limited's (NSE:AMBEY) Business And Shares Still Trailing The MarketAmbey Laboratories Limited's ( NSE:AMBEY ) price-to-earnings (or "P/E") ratio of 22x might make it look like a buy...New Risk • Jun 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (60% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.04b market cap, or US$12.1m).Reported Earnings • Jun 05Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.2% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.01b market cap, or US$11.8m).New Risk • May 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹948.0m market cap, or US$11.1m).Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹45.55, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India.Reported Earnings • Nov 18First half 2025 earnings releasedFirst half 2025 results: EPS: ₹0.16. Net income: ₹29.7m (up ₹29.7m from 1H 2024).New Risk • Sep 15New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (54% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₹1.77b market cap, or US$21.1m).공시 • Sep 13Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024, at 13:00 Indian Standard Time.New Risk • Aug 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (53% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (₹1.96b market cap, or US$23.4m).Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹78.75, the stock trades at a trailing P/E ratio of 43x. Average trailing P/E is 35x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Aug 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹69.20, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 35x in the Chemicals industry in India.Buy Or Sell Opportunity • Jul 23Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at ₹76.85. The fair value is estimated to be ₹97.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last year. Earnings per share has declined by 64%.공시 • Jul 11Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million.Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 330,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,868,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,252,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 936,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,184,000 Price\Range: INR 68 Transaction Features: Regulation S; Rule 144ABoard Change • Jul 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. Independent Director Roni Soni was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.매출 및 비용 세부 내역Dhansa Labs가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NSEI:DHANSA 매출, 비용 및 순이익 (INR Millions)날짜매출순이익일반관리비연구개발비31 Mar 261,4285512031 Dec 251,3785020030 Sep 251,3284429030 Jun 251,3284629031 Mar 251,3294829031 Dec 241,3144728030 Sep 241,2984727030 Jun 241,2596227031 Mar 241,2197728031 Mar 231,0755236031 Mar 228493630031 Mar 2182110328031 Mar 206702520양질의 수익: DHANSA의 비현금 수익 수준이 높습니다.이익 마진 증가: DHANSA의 현재 순 이익률 (3.9%)은 지난해 (3.6%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: DHANSA의 수익은 지난 5년 동안 연평균 10.8% 감소했습니다.성장 가속화: 지난 1년간 DHANSA 의 수익 증가율(15.5%)은 연간 평균(-10.8%)을 초과합니다.수익 대 산업: DHANSA의 지난 1년 수익 증가율(15.5%)은 Chemicals 업계의 11.9%를 상회했습니다.자기자본이익률높은 ROE: DHANSA의 자본 수익률(5.6%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/02 18:45종가2026/05/29 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Dhansa Labs Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.21 (vs ₹2.06 in FY 2025)Full year 2026 results: EPS: ₹2.21 (up from ₹2.06 in FY 2025). Revenue: ₹1.43b (up 7.5% from FY 2025). Net income: ₹55.2m (up 16% from FY 2025). Profit margin: 3.9% (up from 3.6% in FY 2025). The increase in margin was driven by higher revenue.
공시 • May 23Ambey Laboratories Limited to Report Second Half, 2026 Results on May 29, 2026Ambey Laboratories Limited announced that they will report second half, 2026 results on May 29, 2026
공시 • Nov 14Ambey Laboratories Limited to Report First Half, 2026 Results on Nov 14, 2025Ambey Laboratories Limited announced that they will report first half, 2026 results on Nov 14, 2025
Reported Earnings • Sep 08Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.0% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.
Reported Earnings • Jun 05Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.2% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.
Reported Earnings • Nov 18First half 2025 earnings releasedFirst half 2025 results: EPS: ₹0.16. Net income: ₹29.7m (up ₹29.7m from 1H 2024).
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.21 (vs ₹2.06 in FY 2025)Full year 2026 results: EPS: ₹2.21 (up from ₹2.06 in FY 2025). Revenue: ₹1.43b (up 7.5% from FY 2025). Net income: ₹55.2m (up 16% from FY 2025). Profit margin: 3.9% (up from 3.6% in FY 2025). The increase in margin was driven by higher revenue.
공시 • May 23Ambey Laboratories Limited to Report Second Half, 2026 Results on May 29, 2026Ambey Laboratories Limited announced that they will report second half, 2026 results on May 29, 2026
Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 37%After last week's 37% share price gain to ₹37.05, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 2.2% over the past year.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹21.90, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 49% over the past year.
Valuation Update With 7 Day Price Move • Feb 26Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹23.00, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 55% over the past year.
New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹899.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Market cap is less than US$10m (₹899.3m market cap, or US$9.97m).
분석 기사 • Jan 08Ambey Laboratories (NSE:AMBEY) Could Be Struggling To Allocate CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹44.35, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 30% over the past year.
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹1.08b market cap, or US$12.1m).
New Risk • Nov 24New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.05b market cap, or US$11.7m).
분석 기사 • Nov 15There Is A Reason Ambey Laboratories Limited's (NSE:AMBEY) Price Is UndemandingWith a price-to-earnings (or "P/E") ratio of 22.6x Ambey Laboratories Limited ( NSE:AMBEY ) may be sending bullish...
공시 • Nov 14Ambey Laboratories Limited to Report First Half, 2026 Results on Nov 14, 2025Ambey Laboratories Limited announced that they will report first half, 2026 results on Nov 14, 2025
Board Change • Oct 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Sep 08Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.0% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.
공시 • Sep 04Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025, at 15:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹44.75, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 30x in the Chemicals industry in India. Total loss to shareholders of 45% over the past year.
분석 기사 • Jul 19Ambey Laboratories Limited's (NSE:AMBEY) Business And Shares Still Trailing The MarketAmbey Laboratories Limited's ( NSE:AMBEY ) price-to-earnings (or "P/E") ratio of 22x might make it look like a buy...
New Risk • Jun 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (60% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.04b market cap, or US$12.1m).
Reported Earnings • Jun 05Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.2% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.01b market cap, or US$11.8m).
New Risk • May 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹948.0m market cap, or US$11.1m).
Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹45.55, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India.
Reported Earnings • Nov 18First half 2025 earnings releasedFirst half 2025 results: EPS: ₹0.16. Net income: ₹29.7m (up ₹29.7m from 1H 2024).
New Risk • Sep 15New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (54% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₹1.77b market cap, or US$21.1m).
공시 • Sep 13Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024, at 13:00 Indian Standard Time.
New Risk • Aug 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (53% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (₹1.96b market cap, or US$23.4m).
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹78.75, the stock trades at a trailing P/E ratio of 43x. Average trailing P/E is 35x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Aug 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹69.20, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 35x in the Chemicals industry in India.
Buy Or Sell Opportunity • Jul 23Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at ₹76.85. The fair value is estimated to be ₹97.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last year. Earnings per share has declined by 64%.
공시 • Jul 11Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million.Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 330,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,868,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,252,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 936,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,184,000 Price\Range: INR 68 Transaction Features: Regulation S; Rule 144A
Board Change • Jul 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. Independent Director Roni Soni was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.